3 Biotech Stocks with STRONG Momentum

NASDAQ: TGTX | TG Therapeutics, Inc. News, Ratings, and Charts

TGTX – TG Therapeutics (TGTX), Mesoblast (MESO), and Trillium Therapeutics (TRIL) are close to gaining approval for potentially blockbuster drugs. Their stocks are rising in anticipation. Find out whether you should invest.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Cancer has remained one of the biggest challenges for the medical industry in the past 40 years, with no definitive cure to date. Though cancer in its earlier stages is often treatable, the fear of remission remains. Aside from affecting the quality of life, cancer treatments are immensely expensive. According to Zion Market research, the cost of cancer care has increased by 27% in the last decade

The pandemic is leading to even more stress and poor lifestyle choice. Down the road, it could lead to a spike in cancer cases. The direct medical cost of cancer is estimated to be approximately $58 billion in 2020 and will rise at double-digit rates over the next decade according to the National Institutes of Health. However, many pharmaceutical companies have reported progress in developing effective treatments for various types of cancer. 

Companies such as TG Therapeutics, Inc. (TGTX), Mesoblast Ltd. (MESO), and Trillium Therapeutics, Inc. (TRIL) have reported substantial progress in developing effective treatments. These drugs are awaiting approval, but their stocks have soared substantially year-to-date and could gain further. 

TG Therapeutics, Inc. (TGTX)

TGTX is a biopharmaceutical company engaged in the research, development, and commercialization of cancer treatment drugs and autoimmune disease medication. TGTX has gained more than 125% year-to-date. The stock hit its 52-week high of $27.62 on September 2nd

In the past couple of weeks, TGTX successfully rolled out an effective FDA-approved Umbralisib drug for treating different types of lymphoma. It also made significant progress in the development of drugs catering to leukemia. 

The breakthrough advancement in the field of cancer and lymphoma has allowed the company to garner the attention of the global medical industry. TGTX expects to roll out its new drugs for commercial use in the market by the second half of 2020, as well as complete phase three trials and receive FDA approval on two of its drugs currently under development. 

How does TGTX stack up for the POWR Ratings?

A for Trade Grade

B for Buy & Hold Grade

A for Peer Grade

B for Overall POWR Rating. 

It is also ranked #26 out of 373 stocks in the Biotech industry. 

Mesoblast Ltd. (MESO)

MESO develops and supplies regenerative allogeneic cellular medicines. Its proprietary regenerative technology is based on mesenchymal lineage adult stem cells, which targets advanced stages of critical ailments. On September 15th, MESO was awarded the Fierce Biotech Innovation of the Year award for remestemcel-L. 

It received ethics approval and recommendation of the Data Safety Monitoring Board (DSMB) to conduct phase three randomized clinical trials for remestemcel-L in treating critical COVID patients. 

MESO’s breakthrough in this drug drove its earnings for the fourth quarter and fiscal year ended June 2020. It reported a 92% year-over-year increase in net revenue to $32.20 million for fiscal 2020. Milestone revenues increased 127% from the year-ago value to $25 million, while commercialization revenue from sales rose 32% from the same period last year to $6.60 million. MESO’s cash and cash equivalents balance improved 156.5% year-over-year to $129.33 million for fiscal 2020. 

MESO’s EPS is expected to grow at 48.8% per annum over the next five years. Its revenue grew at 45.3% in the trailing twelve months, making it better than 89.1% of the U.S. stocks in the StockNews.com universe. 

MESO has returned over 140% to its investors year-to-date. The stock has gained more than 580% to hit its 52-week high in August since hitting its 52-week low of $3.12 in March. 

Under our POWR Ratings, the company has been accorded a “B” rating in Peer Grade and Industry Rank. In the 232-stock Medical – Pharmaceuticals industry, MESO is ranked #52.

Trillium Therapeutics, Inc. (TRIL)

TRIL, a clinical-stage immuno-oncology company, engages in developing therapies for the treatment of cancer. TRIL’s growth momentum for this year is impressive, as it gained 1324.3% year-to-date. The stock hit its 52-week high of $15.36 on September 14th

TRIL sold 2.30 million shares to Pfizer Inc. (PFE) in exchange for $25 million. The net proceeds from this deal are expected to fund the ongoing clinical trials, working capital requirements, as well as general corporate expenses. TRIL also announced a public offering of 1.50 million shares worth $130 million on September 10th

TRIL is rated a “Strong Buy” in our POWR Ratings system, consistent with its sound business model and solid growth momentum. It also has an “A” in Trade Grade, Buy & Hold Grade and Peer Grade, and “B” in Industry Rank. The stock is ranked #18 out of 232 stocks in the Medical- Pharmaceuticals industry. 

Want More Great Investing Ideas?

7 Best ETFs for the NEXT Bull Market

Is the Stock Market Correction Over?

Chart of the Day- See the Stocks Ready to Breakout


TGTX shares were trading at $24.84 per share on Wednesday afternoon, down $0.39 (-1.55%). Year-to-date, TGTX has gained 123.78%, versus a 6.35% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditi Ganguly


Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TGTXGet RatingGet RatingGet Rating
TRILGet RatingGet RatingGet Rating
Get RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

When Does the Next Bull Run Start?

The 5 month rally for stocks (SPY) was too much, too soon calling into question whether it indeed was a bubble. Thus, not surprising stocks are seeing a healthy correction in September. What matters now is determining when to buy this dip for the next bull run ahead. That is the focus of today’s commentary.

:  |  News, Ratings, and Charts

3 High Profit Mining Stocks Under $10

The pandemic driven weakness in the economy, rising geopolitical tensions, a low interest rate environment, and a volatile market are all favorable for gold and silver to be more and more attractive for investors. As a result, stocks of low-priced miners of these precious metals such as Kinross Gold (KGC), B2Gold Corp (BTG) and Silvercorp Metals (SVM) could generate huge returns.

:  |  News, Ratings, and Charts

If Shares of Wynn Resorts Fall Under This Level, Expect a Breakdown

A support level has formed on the chart of Wynn Resorts (WYNN). If the stock breaks down through this level, expect a drop. Learn when to enter a short position.

:  |  News, Ratings, and Charts

4 Tech Stocks DEFYING the NASDAQ’s Weakness

Many stocks in the Nasdaq Composite index are showing weakness over the last couple weeks. But there are a few showing significant strength over the same time period. Here are four that continue to gain based on their business models and earnings expectations: Zoom Video Communications (ZM), Snap (SNAP), Pinterest (PINS), and Digital Turbine (APPS).

:  |  News, Ratings, and Charts

If Shares of Wynn Resorts Fall Under This Level, Expect a Breakdown

A support level has formed on the chart of Wynn Resorts (WYNN). If the stock breaks down through this level, expect a drop. Learn when to enter a short position.

Read More Stories

More TG Therapeutics, Inc. (TGTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TGTX News